ATS Medical 8-K 2007
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
ATS Medical, Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 1.01 Entry into a Material Definitive Agreement.
On November 14, 2007, ATS Medical, Inc. (the "Company") and Richard A. Curtis, the Company’s Vice President of Corporate Development, entered into a Confidential Separation Agreement and Release (the "Separation Agreement") to set forth the terms and conditions under which Mr. Curtis and the Company will terminate his employment relationship, as described below in Item 5.02.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 15, 2007, the Company and Richard A. Curtis, the Company’s Vice President of Corporate Development, agreed to terminate Mr. Curtis’ employment relationship with the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.